Praxis Precision Medicines (PRAX) financial statements
Praxis Precision Medicines reported revenue of $0 in fiscal 2025, up 249.5% a year over 1 years.
Net income was -$303M.
Free cash flow was -$249M.
The diluted share count rose 21969% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Praxis Precision Medicines's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $2M | $9M | $0 |
| Research and development | $30M | $45M | $120M | $155M | $87M | $152M | $267M |
| Selling, general and admin | $6M | $17M | $47M | $60M | $42M | $56M | $59M |
| Operating income | -$36M | -$62M | -$167M | -$215M | -$126M | -$200M | -$326M |
| Pre-tax income | -$36M | -$62M | -$167M | — | -$123M | -$183M | -$303M |
| Income tax | -$84,000 | -$8,000 | $0 | — | — | — | $471,000 |
| Net income | -$36M | -$62M | -$167M | -$214M | -$123M | -$183M | -$303M |
| EPS (diluted) | -$399.00 | -$117.90 | -$59.10 | -$69.65 | -$18.69 | -$10.21 | -$13.48 |
| Diluted shares | 0M | 1M | 3M | 3M | 7M | 18M | 23M |
| Operating margin | — | — | — | — | -5164.4% | -2340.3% | — |
| Net margin | — | — | — | — | -5037.9% | -2137.5% | — |
Balance sheet
Fiscal years, from Praxis Precision Medicines's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $45M | $297M | $276M | $100M | $81M | $470M | $926M |
| Total current assets | $45M | $302M | $287M | $111M | $85M | $404M | $611M |
| Property, plant and equipment | $128,000 | $82,000 | $1M | $971,000 | $588,000 | $230,000 | $147,000 |
| Total assets | $48M | $303M | $293M | $115M | $88M | $483M | $938M |
| Total current liabilities | $7M | $16M | $38M | $34M | $16M | $38M | $60M |
| Total liabilities | $8M | $16M | $42M | $39M | $18M | $38M | $60M |
| Shareholders' equity | -$81M | $287M | $251M | $76M | $70M | $445M | $878M |
| Net debt | -$45M | -$297M | -$139M | -$62M | -$81M | -$215M | -$357M |
Cash flow
Fiscal years, from Praxis Precision Medicines's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$33M | -$53M | -$125M | -$185M | -$111M | -$132M | -$249M |
| Capital spending | $103,000 | $0 | $1M | $444,000 | $50,000 | $0 | $56,000 |
| Free cash flow | -$34M | -$53M | -$126M | -$185M | -$111M | -$132M | -$249M |
| Stock-based compensation | $668,000 | $5M | $23M | $29M | $25M | $41M | $34M |
| Free cash flow margin | — | — | — | — | -4543.8% | -1540.5% | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for PRAX.
Open PRAX in InvestinglyQuestions
What was Praxis Precision Medicines's revenue in 2025?
$0 in fiscal 2025, from its 10-K filing.
How much free cash flow does Praxis Precision Medicines generate?
-$249M in fiscal 2025 (operating cash flow minus capital spending).
From Praxis Precision Medicines's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.